The article “Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis” evaluates MSC therapy in severe/critical COVID-19 patients. The study found that MSC treatment significantly reduced in-hospital mortality (odds ratio: 0.52) and was associated with fewer adverse events compared to standard care. No significant difference in efficacy was observed across different disease severities or MSC doses. Further high-quality, large-scale trials are needed to confirm these findings.